{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:44:22Z","timestamp":1772811862026,"version":"3.50.1"},"reference-count":20,"publisher":"Cambridge University Press (CUP)","issue":"2","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Can. J. Neurol. Sci."],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"S0317167125000563_as1\">\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Levetiracetam (LEV) is an antiseizure medication (ASM) used as a second line after benzodiazepines for status epilepticus treatment. Current literature lacks direct head-to-head comparisons between different LEV loading dose strategies, leading to uncertainty about superior dosing methods and thus clinical practice variations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0317167125000563_as2\">\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective cohort study was designed to compare efficacy and safety of low (&lt;30 mg\/kg) versus high (\u226530 mg\/kg) weight-based LEV loading doses in adults with benzodiazepine-refractory status epilepticus (BRSE). The primary outcome of this study was termination of BRSE. No requirement for additional ASM after LEV was a surrogate for BRSE termination. Secondary endpoints included endotracheal intubation, intensive care unit (ICU) admission, 30-day all-cause mortality and adverse drug reactions. Statistical analysis included discrete and inferential statistics, including logistic regression and win-ratio analysis, to control for potential confounding variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0317167125000563_as3\">\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Of the 106 patients included in this study, 54 (51%) did not require additional ASM after LEV, thereby achieving seizure termination. There was a higher proportion of patients with seizure termination in the higher weight-based dosing group as compared to the lower weight-based group (66% vs 40%, respectively; aOR 3.07; 95% CI: 1.36\u20137.21). There were lower rates for endotracheal intubation, ICU admission and all-cause mortality in the higher dosing group. Adverse events were comparable between the both groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"S0317167125000563_as4\">\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>LEV\u2019s high weight-based loading dose strategy (\u226530 mg\/kg) is more effective in the termination of BRSE as compared to the lower weight-based loading dose strategy (&lt;30 mg\/kg).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1017\/cjn.2025.56","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T03:45:00Z","timestamp":1743047100000},"page":"266-270","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating Levetiracetam Weight-Based Dosing in Benzodiazepine-Refractory Status Epilepticus"],"prefix":"10.1017","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3710-8099","authenticated-orcid":false,"given":"Nasma","family":"Torfah","sequence":"first","affiliation":[{"name":"Surrey Memorial Hospital"},{"name":"University of British Columbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Lau","sequence":"additional","affiliation":[{"name":"University of British Columbia"},{"name":"Vancouver General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Haag","sequence":"additional","affiliation":[{"name":"University of British Columbia"},{"name":"Vancouver General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Yeom","sequence":"additional","affiliation":[{"name":"University of British Columbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivien","family":"Cao","sequence":"additional","affiliation":[{"name":"University of British Columbia"},{"name":"Vancouver General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trana","family":"Hussaini","sequence":"additional","affiliation":[{"name":"University of British Columbia"},{"name":"Clinical Pharmacy Services"},{"name":"Vancouver General Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"S0317167125000563_ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2013.00192"},{"key":"S0317167125000563_ref8","doi-asserted-by":"publisher","DOI":"10.5698\/1535-7597-16.1.48"},{"key":"S0317167125000563_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"S0317167125000563_ref3","doi-asserted-by":"publisher","DOI":"10.1177\/0883073808331351"},{"key":"S0317167125000563_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30611-5020.10.1016\/S0140-6736(20)30611-5020"},{"key":"S0317167125000563_ref19","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"S0317167125000563_ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-012-9695-z"},{"key":"S0317167125000563_ref15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr352"},{"key":"S0317167125000563_ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01561.x"},{"key":"S0317167125000563_ref2","volume-title":"StatPearls","author":"Wylie","year":"2023"},{"key":"S0317167125000563_ref16","year":"2021"},{"key":"S0317167125000563_ref11","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15791"},{"key":"S0317167125000563_ref1","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13121"},{"key":"S0317167125000563_ref7","doi-asserted-by":"publisher","DOI":"10.1177\/1535759720928269"},{"key":"S0317167125000563_ref20","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.2449"},{"key":"S0317167125000563_ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2024.09.007"},{"key":"S0317167125000563_ref13","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2016.12.1.21"},{"key":"S0317167125000563_ref10","doi-asserted-by":"publisher","DOI":"10.4212\/cjhp.v75i1.3254"},{"key":"S0317167125000563_ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01889.x"},{"key":"S0317167125000563_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2009.05.020"}],"container-title":["Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0317167125000563","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:16:59Z","timestamp":1772792219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0317167125000563\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0317167125000563"],"URL":"https:\/\/doi.org\/10.1017\/cjn.2025.56","relation":{},"ISSN":["0317-1671","2057-0155"],"issn-type":[{"value":"0317-1671","type":"print"},{"value":"2057-0155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]}}}